San Jose BioCenter - Meet With..Merck & Co., Inc.

*If applying Astia members can mention their Astia membership and receive a discount code for 20% off registration fee once application has been accepted.

Agenda
Emerging companies find it increasingly difficult to reach the right person when seeking funding and/or partners. Through the “Meet with…” Series, we provide emerging companies with greater access to partnering and/or financing opportunities.

In this session, Licensing Directors from Merck & Co., Inc. will talk to potential licensees to first explain what they are looking for in a company.

After the presentation, each attendee will be granted a private meeting with Dr. James M. Schaeffer - the Executive Director of Licensing & External Research for Merck Research Laboratories at Merck & Co., Inc. - or Dr. Yael Weiss - the Director of Licensing & External Research for Merck Research Laboratories at Merck & Co., Inc.

Registrations are subject to approval of application.


Application & Costs
Attendees must apply and be approved to attend. To apply, please send your Executive Summary to Aurélie at aurelie@sjbiocenter.com. The Review Board, composed of the BioCenter management team, sponsors, partners and mentors, will meet in early September to consider your application. You will then be notified if your application is accepted or rejected.

• Application fee: FREE
• Registration for one: $100
• Registration for two: $175
• Registration for three: $225
• BioCenter Members: Free
*All registrations include lunch*

About Merck's areas of interest
Merck is a global research-driven pharmaceutical company dedicated to putting patients first. Currently, the therapeutic areas of highest priority for Merck are:  Alzheimer’s disease, atherosclerosis, cardiovascular disease, diabetes, novel vaccines, obesity, oncology, sarcopenia, and schizophrenia. In addition, and importantly for licensing, the following other areas remain of high interest for focused investment in new compounds and mechanisms: antibiotics, antifungals, antivirals (HCV and HIV), asthma, COPD, neurodegenerative diseases, osteoporosis, and circadian disorders. In other disease areas Merck will continue to pursue external licensing when attractive opportunities for compounds with clinical proof of concept become available.  Merck remains very interested in accessing research technologies which will enable/advance current projects; this includes bioinformatics IT, biologic platforms, drug delivery (including nucleotides), peptide therapeutics, molecular biomarkers and RNA therapeutics.
Click here to view Merck's areas of interest»